Asahi Kasei Pharma

21 articles about Asahi Kasei Pharma

• AGC Biologics Partners with Asahi Kasei Pharma Corporation on Clinical Antibody Project

  8/15/2023

  AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization, announced a new agreement with Asahi Kasei Pharma Corporation to produce clinical drug substance for antibody-based therapies at AGC Biologics’ Seattle manufacturing site.

• Basilea announces CHF 5 million milestone payment from Asahi Kasei Pharma for antifungal Cresemba® (isavuconazole) in Japan

  3/23/2023

  Basilea Pharmaceutica Ltd announced that its license partner Asahi Kasei Pharma has reported the achievement of a milestone related to the launch of Cresemba® in Japan, which triggered a CHF 5 million payment from AKP to Basilea.

• Asahi Kasei Pharma to Sponsor Research for Drug Discovery Research and Technology: Open Innovation 2023

  10/13/2022

  Asahi Kasei Pharma is publicly calling for new proposals for drug development research as part of its efforts for open innovation to promote pharmaceutical research and development through enhanced cooperation with universities, research institutes and enterprises around the world.

• Basilea’s partner Asahi Kasei Pharma filed New Drug Application for the marketing authorization of isavuconazole in Japan

  9/30/2021

  Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma) has filed a New Drug Application (NDA) for the marketing authorization of isavuconazole (Cresemba ® ) in Japan for the treatment of the fungal infections aspergillosis, mucormycosis and cryptococcosis.

• AgNovos Healthcare and Asahi Kasei Pharma Enter Into an Exclusive Option Agreement for Japan

  9/29/2021

  AgNovos Healthcare, LLC and Asahi Kasei Pharma Corporation announced that the companies have entered into an exclusive option agreement for the commercialization of AgNovos’ AGN1 LOEP Hip Kit in Japan.

• Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate

  1/28/2021

  Eli Lilly and Company (NYSE: LLY) and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clini

• 

  4 New Life Sciences Licensing Deals and Investments to Watch

  1/28/2021

  Today marked some wheeling and dealing in the life sciences industry as several companies licensed products or invested in other companies. Here’s a look.

• Evotec AG Release: Company Enters Into An Integrated Drug Discovery Collaboration With Asahi Kasei Pharma

  1/19/2017

• Array BioPharma Licenses TrkA inhibitors to Asahi Kasei Pharma for Up to $76 Million

  3/31/2016

• Asahi Kasei Pharma Selects Evotec AG As Its Partner For Ion Channel Drug Discovery

  3/26/2015

• Vernalis PLC And Asahi Kasei Pharma Achieve Research Milestone

  3/6/2015

• Vernalis PLC And Asahi Kasei Pharma Achieve Milestone

  3/27/2014

• Vernalis PLC Enters Into Research Collaboration With Asahi Kasei Pharma

  10/1/2013

• Asahi Kasei Pharma Acquires Artisan Pharma, Inc. to Establish U.S. Presence; Wholly-owned Subsidiary Changes Name to Asahi Kasei Pharma America Corp.

  11/22/2011

• Zosano Pharma, Inc. and Asahi Kasei Pharma Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone(TM) (teriparatide acetate)

  10/10/2011

• Actelion Ltd. Shares Slump After Asahi Kasei Pharma Case Decision; Asahi Awarded up to $547 Million

  5/2/2011

• Auxilium Pharmaceuticals and Asahi Kasei Pharma Enter Agreement to Develop, Commercialize and Supply XIAFLEX(R) In Japan

  3/22/2011

• Asahi Kasei Pharma And CoTherix, Inc. Conclude Licensing Agreement For Fasudil, Rho-kinase Inhibitor

  7/6/2006

• CoTherix, Inc. Gets Rights From Asahi Kasei Pharma For Fasudil; CoTherix To Make Upfront Payment Of $8.75 Million

  6/28/2006

• Asahi Kasei Pharma And Eisai Company, Ltd. In Sales Promotion Agreement For Eril In China

  4/5/2006